- Home
- AHG vs CMPX Comparison
AHG vs CMPX Comparison
Compare AHG & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AHG
- CMPX
- Stock Information
- Founded
- AHG 2013
- CMPX 2014
- Country
- AHG China
- CMPX United States
- Employees
- AHG N/A
- CMPX N/A
- Industry
- AHG Business Services
- CMPX Biotechnology: Pharmaceutical Preparations
- Sector
- AHG Consumer Discretionary
- CMPX Health Care
- Exchange
- AHG Nasdaq
- CMPX Nasdaq
- Market Cap
- AHG 245.7M
- CMPX 206.3M
- IPO Year
- AHG N/A
- CMPX N/A
- Fundamental
- Price
- AHG $1.23
- CMPX $1.39
- Analyst Decision
- AHG
- CMPX Strong Buy
- Analyst Count
- AHG 0
- CMPX 3
- Target Price
- AHG N/A
- CMPX $7.67
- AVG Volume (30 Days)
- AHG 362.9K
- CMPX 450.8K
- Earning Date
- AHG 12-27-2024
- CMPX 11-12-2024
- Dividend Yield
- AHG N/A
- CMPX N/A
- EPS Growth
- AHG N/A
- CMPX N/A
- EPS
- AHG N/A
- CMPX N/A
- Revenue
- AHG $2,414,338.00
- CMPX $850,000.00
- Revenue This Year
- AHG N/A
- CMPX N/A
- Revenue Next Year
- AHG N/A
- CMPX $610.48
- P/E Ratio
- AHG N/A
- CMPX N/A
- Revenue Growth
- AHG N/A
- CMPX N/A
- 52 Week Low
- AHG $0.60
- CMPX $0.77
- 52 Week High
- AHG $2.90
- CMPX $2.34
- Technical
- Relative Strength Index (RSI)
- AHG 55.14
- CMPX 42.05
- Support Level
- AHG $0.82
- CMPX $1.33
- Resistance Level
- AHG $1.90
- CMPX $1.58
- Average True Range (ATR)
- AHG 0.27
- CMPX 0.12
- MACD
- AHG 0.05
- CMPX -0.02
- Stochastic Oscillator
- AHG 41.74
- CMPX 18.09
About AHG Akso Health Group ADS
Akso Health Group formerly Xiaobai Maimai Inc is a social e-commerce platform based in China. The company collaborates with domestic e-commerce platforms and offers users a wide selection of high-quality and affordable products on its social e-commerce platform. It generates majority of the revenues from sale of medical devices business.
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to broadly drug the immune system and identify optimal combinations empirically. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of three product candidates, CTX-009, CTX-471, and CTX-8371.